Literature DB >> 24362789

Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population.

Hsin-Hung Chen1, Su-Yin Yeh, Hue-Yong Chen, Cheng-Li Lin, Fung-Chang Sung, Chia-Hung Kao.   

Abstract

This study evaluated whether people with ankylosing spondylitis (AS) and spondyloarthritis are at higher risk of type 2 diabetes mellitus (T2DM). We used a sub-dataset of the National Health Insurance Research Database from 1996 to 2010 to established a AS cohort consisting new patients with AS or spondyloarthritis (N = 7,778) and a non-AS cohort without the diseases (N = 31,112). Incidences of T2DM in the two cohorts, hazard ratios (HRs) of risk of T2DM in association with AS, and cumulative probability of having T2DM were estimated by the end of 2010. The incidence of T2DM was 1.17-fold higher in the AS cohort than in the non-AS cohort (13.5 vs. 11.5, per 1,000 person-years), with an adjusted HR of 1.16 (95 % CI = 1.05-1.29). The T2DM incidence was higher for women than for men; while the Cox model measured sex-specific adjusted HR of T2DM was higher for men than for women. The incidence rate of T2DM increased with age in both cohorts, while the age-specific measures showed that the adjusted HR of T2DM was higher in young AS patients (≤50 years of age) than older ones, compared to their peers of non-AS group. The plot of Kaplan-Meier analysis showed that the overall probability of having T2DM was 2 % higher in the AS cohort than in the non-AS cohort (log-rank test: p < 0.0001). Patients with AS and spondyloarthritis have an increased risk of developing T2DM.

Entities:  

Mesh:

Year:  2013        PMID: 24362789     DOI: 10.1007/s00296-013-2927-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  35 in total

1.  Prevention of type 2 diabetes in youth: etiology, promising interventions and recommendations.

Authors:  Lorrene D Ritchie; Sujatha Ganapathy; Gail Woodward-Lopez; Dana E Gerstein; Sharon E Fleming
Journal:  Pediatr Diabetes       Date:  2003-12       Impact factor: 4.866

Review 2.  Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Sylvain Mathieu; Laure Gossec; Maxime Dougados; Martin Soubrier
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

3.  High association of an HL-A antigen, W27, with ankylosing spondylitis.

Authors:  L Schlosstein; P I Terasaki; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

4.  Increased levels of acute-phase serum proteins in diabetes.

Authors:  D E McMillan
Journal:  Metabolism       Date:  1989-11       Impact factor: 8.694

Review 5.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.

Authors:  Mike J Peters; Irene E van der Horst-Bruinsma; Ben A Dijkmans; Michael T Nurmohamed
Journal:  Semin Arthritis Rheum       Date:  2004-12       Impact factor: 5.532

Review 6.  A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus.

Authors:  Jeffrey S Freeman
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

7.  Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones.

Authors:  K L Svenson; G Lundqvist; L Wide; R Hällgren
Journal:  Metabolism       Date:  1987-10       Impact factor: 8.694

8.  HLA-A, -B, and -DR associations in type I diabetes mellitus with onset after age forty.

Authors:  W B Pittman; R T Acton; B O Barger; D S Bell; R C Go; C C Murphy; J M Roseman
Journal:  Diabetes       Date:  1982-02       Impact factor: 9.461

9.  Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance.

Authors:  K L Svenson; T Pollare; H Lithell; R Hällgren
Journal:  Metabolism       Date:  1988-02       Impact factor: 8.694

10.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

View more
  11 in total

1.  Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk.

Authors:  Diego Germano Maia; Kristopherson Lustosa Augusto; Mailze Campos Bezerra; Carlos Ewerton Maia Rodrigues
Journal:  Clin Rheumatol       Date:  2017-04-08       Impact factor: 2.980

2.  Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis.

Authors:  Santhi Mantravadi; Michael George; Colleen Brensinger; Min Du; Joshua F Baker; Alexis Ogdie
Journal:  BMC Rheumatol       Date:  2020-09-02

Review 3.  Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Authors:  Silvia Scriffignano; Fabio Massimo Perrotta; Antonia De Socio; Ennio Lubrano
Journal:  Clin Rheumatol       Date:  2018-10-18       Impact factor: 2.980

4.  Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis.

Authors:  Jean W Liew; Michael M Ward; John D Reveille; Michael Weisman; Matthew A Brown; MinJae Lee; Mohammed Rahbar; Susan R Heckbert; Lianne S Gensler
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11       Impact factor: 4.794

5.  Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study.

Authors:  Jean W Liew; John D Reveille; Maria Castillo; Henna Sawhney; Benjamin S Naovarat; Susan R Heckbert; Lianne S Gensler
Journal:  J Rheumatol       Date:  2020-07-01       Impact factor: 4.666

6.  Identification of disease comorbidity through hidden molecular mechanisms.

Authors:  Younhee Ko; Minah Cho; Jin-Sung Lee; Jaebum Kim
Journal:  Sci Rep       Date:  2016-12-19       Impact factor: 4.379

Review 7.  The Efficacy and Safety of Simple-Needling Therapy for Treating Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yichen Xuan; Hui Huang; Yiyong Huang; Duanyong Liu; Xiuwu Hu; Lele Geng
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-13       Impact factor: 2.629

8.  Impact of ankylosing spondylitis on depression: a nationwide cohort study.

Authors:  Jin-Sung Park; Hae-Dong Jang; Jae-Young Hong; Ye-Soo Park; Kyungdo Han; Seung-Woo Suh; Si-Yong Park; Bo-Taek Kim
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

9.  Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set.

Authors:  Jessica A Walsh; Xue Song; Gilwan Kim; Yujin Park
Journal:  J Pharm Health Serv Res       Date:  2018-01-16

10.  The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study.

Authors:  Rikke A Andreasen; Lars E Kristensen; Kenneth Egstrup; Xenofon Baraliakos; Vibeke Strand; Hans Christian Horn; Inger M J Hansen; Robin Christensen; Torkell Ellingsen
Journal:  Arthritis Res Ther       Date:  2019-10-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.